Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05331664 · ClinicalTrials.gov registry record · Phase 4
Dropless Pars Plana Vitrectomy Study
A Phase 4 study of Rhegmatogenous Retinal Detachment, sponsored by Massachusetts Eye and Ear Infirmary.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 168
- Enrollment target
- 1
- Study location
NCT05331664: Recruiting Phase 4 study of Rhegmatogenous Retinal Detachment, sponsored by Massachusetts Eye and Ear Infirmary.
NCT05331664 is a Phase 4 study of Rhegmatogenous Retinal Detachment that is actively recruiting participants, run by Massachusetts Eye and Ear Infirmary. The registered enrollment target is 168 participants, below the 329-participant average among 3 other Rhegmatogenous Retinal Detachment trials with a reported enrollment target (49% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05331664, a Phase 4 study of Rhegmatogenous Retinal Detachment, is actively recruiting participants, sponsored by Massachusetts Eye and Ear Infirmary.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 168 participants
- Enrollment target
- 1
- Study location
Study Summary
To demonstrate that intraoperative use of subtenon triamcinolone acetonide at the time of surgery without postoperative eye drops is non-inferior to the regimen of postoperative eye drops following primary pars plana vitrectomy for retinal detachment.
Primary Outcome
Mean anterior chamber cell based on SUN (Standardization of Uveitis Nomenclature) criteria as measured by Slit Lamp Biomicroscopy
Conditions Studied
Interventions
- DRUG Atropine 1%
- PROCEDURE Pars plana vitrectomy
- DRUG Triamcinolone Acetonide 40mg/mL
- DRUG Moxifloxacin 0.5% or Polymyxin/Trimethoprim if patient is allergic to moxifloxacin
- DRUG Prednisolone 1%
Study Locations (1)
Massachusetts
- Massachusetts Eye and Ear - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 168 participants |
| Start Date | 2022-07-25 |
| Est. Completion | 2027-01-30 |
| Phase | Phase 4 |
What NCT05331664 shows while recruiting
NCT05331664 is an interventional study that assigns participants to a tested intervention. The registered 168 participants enrollment target is mid-sized for trials with a published cap, below the 329-participant average among 3 other Rhegmatogenous Retinal Detachment trials with a reported enrollment target (49% lower).
The record links to 1 condition, with Rhegmatogenous Retinal Detachment appearing as the primary indexed condition, and to 5 interventions - of which Atropine 1% is the first listed.
NCT05331664 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05331664 about?
NCT05331664 is a clinical study titled "Dropless Pars Plana Vitrectomy Study". To demonstrate that intraoperative use of subtenon triamcinolone acetonide at the time of surgery without postoperative eye drops is non-inferior to the regimen of postoperative eye drops following primary pars plana vitrectomy for retinal detachment.
What is the current status of trial NCT05331664?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 168 participants. The study started on 2022-07-25. Estimated completion is 2027-01-30.
What conditions does trial NCT05331664 study?
This clinical trial studies the following conditions: Rhegmatogenous Retinal Detachment.
What interventions are being tested in trial NCT05331664?
The interventions under investigation include: Atropine 1% (DRUG), Pars plana vitrectomy (PROCEDURE), Triamcinolone Acetonide 40mg/mL (DRUG), Moxifloxacin 0.5% or Polymyxin/Trimethoprim if patient is allergic to moxifloxacin (DRUG), Prednisolone 1% (DRUG).
Who is sponsoring clinical trial NCT05331664?
This trial is sponsored by Massachusetts Eye and Ear Infirmary, which has 73 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05331664 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rhegmatogenous Retinal Detachment
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Prevention of ProliFerative Vitreoretinopathy with Intravitreal MethotreXate in Primary Retinal DEtachment Repair (FIXER) Trial
RECRUITING · Phase 2
-
Topical Netarsudil for the Prevention of Proliferative Vitreoretinopathy in Patients With Retinal Detachment
RECRUITING · Phase 1
-
A Multi-Center Study on the Use of Rho-Kinase Inhibitor to Reduce or Prevent PVR in RRD Eyes at High Risk for PVR
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02118922 · 168 participants
A Study to Test the Diagnostic Potential of Brillouin Microscopy for Corneal Ectasia
- NCT03536897 · 168 participants
IORT Following Breast Conserving Surgery for Early Stage Breast Cancer Registry
- NCT04078230 · 168 participants · NA
Regional or Extend LymphAdenectomy During Resection of Intrahepatic Cholangiocarcinoma
- NCT04159168 · 168 participants · NA
Facial Affect Sensitivity Training for Young Children With Callous-unemotional Traits
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI